In experiments on animals with Lewis lung carcinoma, emoxipin decreased hematotoxicity of cyclophosphamide without reducing its antitumor efficiency (effect on primary tumor node). Combined administration of emoxipin and cyclophosphamide more effectively prevented the development of metastases compared to cytostatic monotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
T. A. Bogush and E. A. Bogush, Vopr. Onkol., 41, No. 2, 52–53 (1995).
E. D. Gol'dberg and T. G. Borovskaya, Byull. Eksp. Biol. Med., 135, No. 3, 244–251 (2003).
M. D. Mashkovskii, Drugs [in Russian], Moscow (2007), p. 732.
N. A. Mufazalova, I. D. Treshchalin, E. M. Treshchalina, et al., Byull. Eksp. Biol. Med., 137, No. 1, 45–47 (2004).
V. V. Novitskii, E. A. Stepovaya, N. G. Bazhenova, et al., Eksp. Klin. Farmakol., 62, No. 1, 56–59 (1999).
Manual on Experimental (Preclinical) Testing of New Pharmacological Agents [in Russian], Ed. R. U. Khabriev, Moscow (2005), pp. 674–682.
Author information
Authors and Affiliations
Corresponding author
Additional information
__________
Translated from Byulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 146, No. 7, pp. 72–75, July, 2008
Rights and permissions
About this article
Cite this article
Siprov, A.V., Kinzirskaya, Y.A. The use of emoxipin for correction of cyclophosphamide cytotoxicity in experimental animals. Bull Exp Biol Med 146, 66–69 (2008). https://doi.org/10.1007/s10517-008-0207-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-008-0207-2